Ultimately, long-term studies are needed to clarify the impact of these newly licensed IBAT inhibitors on HCC risk in BSEP-deficient patients as well as other patient groups at risk of HCC. The gene discussed is ABCB11; the disease is hepatocellular carcinoma.